Compare Archer-Daniels-Midland Co (ADM) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer-Daniels-Midland Co vs BridgeBio Pharma Inc — how do they compare? Archer-Daniels-Midland Co trades at $80.04 (market cap $37.69B), while BridgeBio Pharma Inc trades at $77.15 (market cap $15.26B). The key difference: Archer-Daniels-Midland Co is far larger — about 2.5× BridgeBio Pharma Inc's market cap, and Archer-Daniels-Midland Co pays a 2.66% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| ADM | BBIO | |
|---|---|---|
Market Cap | $37.69B | $15.26B |
Sector | Consumer Staples | Health |
52-Week High | $84.11 | $79.91 |
52-Week Low | $53.54 | $43.19 |
Enterprise Value | $47.72B | $16.81B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
BridgeBio Pharma (BBIO) trades at $77.91, up 0.93% on the day, supported by a bullish technical outlook and strong analyst consensus. The stock shows robust revenue growth, with 2025 revenue reaching $502.08M, though it remains unprofitable with a net income margin of -124.41%. Recent positive news includes a $1 billion preferred equity raise and regulatory progress for key drug candidates, fueling investor optimism despite ongoing cash burn from operations.
The investment case hinges on the company's pipeline catalysts and commercial execution, with a consensus price target of $102.75 implying significant upside. However, high cash burn, negative equity, and consistent earnings misses present substantial risks, requiring careful monitoring of upcoming clinical and regulatory milestones for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
